ClinicalTrials.gg
Active, not recruitingNCT05520567Updated Sep 11, 2026

A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia

A Phase 1/2 interventional study of Gilteritinib and Venetoclax in Acute Myeloid Leukemia (AML) and FLT3-mutated Acute Myeloid Leukemia, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-11.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute — 13 open to participants now, 15 under way, 6 of them phase 3. gilteritinib · Leukemia, Myeloid, Acute.

Planned enrollment
20th of 31
70 · median 97
Started
2023
with 1 other
Phase 1/2
8 of 31
2 open now
Primary completion
2028-07
later than 6 of 14 live
Registered
23rd of 31
by date
Lead sponsor
10 of 31
Astellas Pharma Global Development, Inc.

Among the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, this one is the 20th largest by planned enrollment, is one of 2 that started in 2023, is one of 8 in phase 1/2, reaches primary completion later than 6 of the 14 other live ones, and was the 23rd registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

13 of the 31 studies testing gilteritinib in Leukemia, Myeloid, Acute are open now, in 7 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About gilteritinib

gilteritinib: first FDA approval 2018 (XOSPATA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing gilteritinib in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

People with acute myeloid leukemia (AML) are usually treated with chemotherapy. Some people with AML have a changed FLT3 gene which causes leukemia cells to grow faster. Therefore, chemotherapy is less suitable to treat AML in people with the changed FLT3 gene.

Gilteritinib, given with venetoclax and azacitidine, is a potential new treatment for people with AML with the changed FLT3 gene. They cannot have chemotherapy due to old age or other conditions. Before these combined 3 medicines are available as a treatment, the researchers need to understand how they are processed by and act upon the body when given together. In this study, they do this to find a suitable dose for venetoclax and to check for potential medical problems from the treatment.

In this study, people newly diagnosed with AML who have the changed FLT3 gene and cannot have chemotherapy can take part.

The main aims of this study are: to find suitable doses of gilteritinib, venetoclax and azacitidine as a combined treatment; to learn how they are processed by and act upon the body; to learn the remission rate; to check for medical problems during this treatment.

In the study, people will visit the study clinic many times. The first visit is to check if they can take part. People will be asked about their medical history, have a medical examination, and have their vital signs checked. Also, they will have an ECG to check their heart rhythm and have some blood and urine samples taken for laboratory tests. They will have a chest X-ray and a bone marrow sample will be taken. The changed FLT3 gene will be confirmed, either by the bone marrow or a blood sample.

This study will be in 2 phases.

In Phase 1, different small groups of people will take venetoclax tablets containing lower to higher doses in the combined treatment. The doses of gilteritinib and azacytidine will be unchanged. This is done to find a suitable dose of venetoclax to use in phase 2 of the study. People will take tablets of gilteritinib and venetoclax once a day on a 28-day cycle. They will be given azacytidine as an infusion or an injection just under the skin. This will be for 7 days at the beginning of each 28-day cycle. They will continue cycles of treatment throughout this phase of the study.

In Phase 2, more people newly diagnosed with AML with the changed FLT3 gene will take part. They will be treated with the suitable doses of the combined treatment worked out from Phase 1. Treatment will be on a 28-day cycle. People will continue on cycles of treatment throughout this phase of the study.

Researchers will work out the remission rate from this phase of the study. In each phase of the study, people can continue with up to 12 cycles of treatment if they can manage any medical problems. People will visit the study clinic many times during their first treatment cycle, and less often during the next cycles. During these visits, medical problems will be recorded and some blood samples will be taken for laboratory tests. On some visits, people will also have their vital signs checked. Bone marrow samples will be taken during cycle 1, and at the beginning of cycle 3. More samples will be taken during the study from people who are not in remission.

When people have finished treatment, those who have responded well to treatment and are in remission will be invited to continue with up to 24 more cycles of gilteritinib plus azacitidine.

All people taking part in the study will visit the study clinic for an end-of-treatment visit. During this visit, medical problems will be recorded and some blood samples will be taken for laboratory tests. People will have a medical examination, an ECG, and will have their vital signs checked. Also, a bone marrow sample will be taken. There will be a follow-up visit 30 days later to check for medical problems. Then people will visit the clinic or get a phone call every 3 months for up to 3 years. This is to give an update on their current treatment for AML.

Some people can have a stem cell transplant during the study if they meet certain study rules. They will pause their study treatment during the stem cell transplant process and continue study treatment afterwards.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)
  • FLT3-mutated Acute Myeloid Leukemia

Keywords

  • Cancer
  • Acute Myeloid Leukemia
  • AML
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has a diagnosis of previously untreated Acute Myeloid Leukemia (AML) according to World Health Organization classification as determined by pathology review at the treating institution.
  • Participant is positive for FMS-like tyrosine kinase 3 (FLT3) mutation (internal tandem duplication [ITD] and/or tyrosine kinase domain [TKD] [D835/I836] mutation) in bone marrow or whole blood as determined by the central laboratory. A participant with rapidly proliferative disease and unable to wait for the central laboratory results can be enrolled from a local test result.
  • Participant is ineligible for intensive induction chemotherapy by meeting at least 1 of the following criteria:

    • Participant is >= 75 years of age with (ECOG) performance status 0, 1, or 2.
    • Participant is >= 18 to 75 years of age and has any of the following comorbidities: ECOG performance status 2 or 3, cardiac history of congestive heart failure requiring treatment or \<= 50% or chronic stable angina, known history of diffusion capacity of lung for carbon monoxide (DLCO) \<= 65% or (FEVI) \<= 65%, > 30 mL/min to 45 mL/min, calculated by the Cockcroft Gault formula, moderate hepatic impairment with total > 1.5 to \< 3.0 x (ULN), any other comorbidity incompatible with intensive chemotherapy during screening and before enrollment.
  • Participant must have a projected of at least 12 weeks.
  • Participant must have adequate organ and bone marrow function prior to enrollment, as specified per protocol's laboratory parameters.
  • Participant is suitable for oral administration of study drug (gilteritinib and venetoclax) and is willing/able to swallow oral tablets/capsules.
  • Participant with a known history of (HIV) on effective antiretroviral therapy must have a viral load undetectable for 6 months prior to Cycle 1 Day 1 (C1D1).
  • Female participant is eligible to participate if she is not pregnant and at least one of the following conditions apply:

    • Not a woman of (WOCBP) OR
    • WOCBP agrees to follow the guidance starting at screening and continue through the study treatment period, and for at least 180 days after the final study regimen administration.

WOCBP must have a negative pregnancy test during screening.

  • Female participant must agree not to breastfeed starting at screening, throughout the study treatment period and for 60 days after the last dose of the study treatment regimen.
  • Female participant must not donate ova starting at screening, throughout the study treatment and for 180 days after the last dose of the study treatment regimen.
  • Male participant with female partner(s) of childbearing potential must agree to use contraception starting at screening and continue through the study treatment, and for at least 120 days after the last dose of the study treatment regimen.
  • Male participant must not donate sperm starting at screening, throughout the study treatment and for 120 days after the last dose of the study treatment regimen. (Venetoclax may cause a decrease in spermatogenesis. Male participant considering preservation of fertility should bank sperm before initiating treatment with venetoclax.)
  • Male participant with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the treatment period, and for 120 days after the final study drug administration.
  • Participant agrees not to participate in another interventional study while on treatment in this study.

Exclusion criteria

Exclusion Criteria:

  • Participant with the following conditions:

    • Acute promyelocytic leukemia (APL)
    • Active, symptomatic central nervous system (CNS) involvement with AML
    • History of myeloproliferative neoplasm (MPN), including myelofibrosis, essential thrombocythemia, polycythemia vera, chronic myeloid leukemia (CML) with or without BCR-ABL1 translocation or AML with BCR-ABL1 translocation
  • Participant previously treated with CAR-T cell therapy for AML or MDS. Exceptions for prior treatment of AML are (i.e., the following treatments are allowed):

    • Hydroxyurea for increased blast count (No required. It can be continued throughout the first cycle of therapy).
    • Leukapheresis for leukocytosis (No washout period required. It can be continued during the study).
    • Preemptive treatment with retinoic acid prior to exclusion of APL \< 7 days.
  • Participant who is receiving treatment with any other agents.
  • Participant requires treatment with concomitant drugs that are strong or moderate inducers of cytochrome P450 (CYP)3A or P glycoprotein (P-gp) during study treatment.
  • Participant who has consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or starfruit \<= 3 days prior to C1D1.
  • Participant with a cardiovascular disability status of (NYHA) Class >= 3.
  • Participant with mean > 450 msec at screening based on local reading performed in triplicate.
  • Participant with a history of Long QT Syndrome at screening.
  • Participant has been diagnosed with another within 2 years prior to screening for the study, with the following exceptions:

    • Adequately treated in situ carcinoma of the cervix uteri or carcinoma in situ of breast;
    • Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin;
    • Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
    • Participants who are on maintenance therapy for malignancies with no evidence of active malignancy for >= 2 years and the maintenance therapy can be discontinued.
  • Participant who has an uncontrolled intercurrent illness including, but not limited to any of the following conditions:

    • Uncontrolled hypertension
    • Active, uncontrolled infection (viral, bacterial or fungal): An infection controlled with an approved or closely monitored antibiotic/antifungal treatment is allowed.
    • Symptomatic, congestive heart failure
    • Unstable angina pectoris
    • Chronic respiratory disease that requires continuous oxygen
    • Psychiatric illness/social situations that would limit compliance with study requirements
    • Any other illness or condition that would interfere with study compliance or would compromise the participant's safety or study endpoints, including any to gilteritinib, azacitidine or venetoclax listed in the country package insert.
  • Participant who has gastrointestinal disorders, malabsorption or other abnormalities that would interfere with absorption of the oral study drug.
  • Participant has active or C or other active hepatic disorder.

    • Participant with positive hepatitis B surface antigen (HBsAg) or detectable hepatitis B virus (HBV) deoxyribonucleic acid (DNA) are not eligible.
    • Participant with negative HBsAg, positive hepatitis B core antibody and negative hepatitis B surface antibody will be eligible if HBV DNA is undetectable.
    • For participant with a known history of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy, if indicated, to be eligible for this study.
    • Participant with antibodies to virus (HCV) will be eligible if hepatitis C ribonucleic acid (RNA) viral load is undetectable.
    • Participant with a known history of HCV infection must have been treated and cured to be eligible for this study. Participants with HCV infection who are currently on treatment are eligible if they have an undetectable HCV viral load.
  • Participant has had major surgery within 4 weeks prior to the first study dose.
  • Participant has a known or suspected to gilteritinib, azacitidine or venetoclax or any components of the formulations used.
  • Participant with recent positive test for SARS-CoV-2 ( or diagnosed with COVID-19) and no follow up test with negative result cannot be enrolled. Participant with contact to persons with COVID-19 and participants with signs and symptoms for COVID-19 infection must be tested before enrolling.
  • Participant who requires concomitant treatment with a strong or moderate P-gp or iinhibitor, with the exception of posaconazole, for antifungal prophylaxis during cycle 1 of the Dose Ranging Phase (phase 1). Note: Posaconazole is the only strong CYP3A inhibitor antifungal allowed during the cycle 1 DLT evaluation period. Post-DLT evaluation period, other antifungals including strong or moderate CYP3A inhibitors are allowed throughout the study.
  • Participant does not have any of the following mutations:

FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    Dose Ranging Cohort (Phase 1)

    Participants will receive daily dose of gilteritinib and venetoclax for 28 days, and azacitidine for 7 days in each 28-day cycle.

    Drug: Gilteritinib · Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Dose Expansion Cohort (Phase 2)

    Participants will receive daily dose of gilteritinib, venetoclax, and azacitidine at an optimized dose established from dose ranging cohort (Phase 1)

    Drug: Gilteritinib · Drug: Venetoclax · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities (DLTs)

    A DLT is defined as any of the events meeting DLT criteria that occur with the first dose on Cycle 1 Day 1 (C1D1) and that is considered to be possibly or probably related to the study treatment regimen.

    Time frame: Up to 42 Days

  2. Number of Participants with Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical study participant temporally associated with the use of study investigational product (IP), whether or not considered related to the study IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study IP. This includes events related to the comparator and events related to the (study) procedures.

    Time frame: Up to 49 months

  3. Number of Participants with Serious AEs (SAEs)

    An SAE is defined as any untoward medical occurrence that, at any dose: * results in death * is life threatening * requires inpatient hospitalization or prolongation of existing hospitalization * results in persistent or significant disability/incapacity * is a congenital anomaly/birth defect * other situations where medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in other situations such as important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed above. These events should usually be considered serious.

    Time frame: Up to 49 months

  4. Number of Participants with laboratory value abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to 48 months

  5. Number or Participants with electrocardiogram (ECG) abnormalities and/or AEs

    Number of participants with potentially clinically significant ECG values.

    Time frame: Up to 48 months

  6. Number of Participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to 48 months

  7. Number of Participants with physical exam abnormalities and/or AEs

    Number of participants with potentially clinically significant physical exam values.

    Time frame: Up to 48 months

  8. Number of Participants at each grade of the Eastern Cooperative Oncology Group (ECOG) performance status scores

    The ECOG scale will be used to assess performance status. Grades range from 0 (fully active) to 5 (dead). Negative change scores indicate an improvement. Positive scores indicate a decline in performance.

    Time frame: Up to 48 months

  9. Percentage of Participants with Complete Remission (CR)

    CR rate is defined as the number of participants who achieve the best response of CR divided by the number of participants in the analysis population. CR is defined as participants having bone marrow regenerating normal hematopoietic cells and achieve a morphologic leukemia-free state and must have bone marrow blasts \< 5% by morphological examination, absolute neutrophil count (ANC) \> 1 x 10\^9/L, platelet count \> 100 x 10\^9/L, and an absence of leukemic blasts in the peripheral blood by morphological examination. There should be no evidence of extramedullary disease. Other participants who do not relapse on study are considered nonevents and censored at the last

    Time frame: Up to 24 months

  10. Pharmacological activity by Plasma Inhibitory Activity Assay (PIA)

    Inhibition of FLT3 phosphorylation after drug treatment will be determined relative to pretreatment phosphorylated FLT3 levels in participants to assess the relationship with gilteritinib dose. Phosphorylated FLT3 will be measured by plasma inhibitory activity (PIA) assay.

    Time frame: Up to 2 months

  11. Pharmacokinetics (PK) of ASP2215 in plasma: concentration

    Concentration will be recorded from the PK plasma samples collected.

    Time frame: Up to 6 months

Secondary outcomes

  1. Percentage of Participants with Complete Remission and Complete Remission with Partial Hematological Recovery (CR/CRh) rate

    The CR/CRh rate is defined as the number of participants who achieved either CR or CRh at any of the post baseline visits divided by the number of participants in the analysis population.

    Time frame: Up to 24 months

  2. Percentage of Participants with Composite Complete Remission (CRc)

    CRc rate is defined as the number of participants who achieve the best response of CRc divided by the number of participants in the analysis population.

    Time frame: Up to 24 months

  3. Duration of Remission (DOR)

    Duration of remission includes duration of CRc, CR, CR/CRh, CRh, complete remission with incomplete hematologic recovery (CRi), complete remission with incomplete platelet recovery (CRp). Duration of CRc is defined as the time from the date of first CRc until the date of confirmed relapse or death due to any cause for participants who achieve CRc. Participants without confirmed relapse or death will be censored at their last relapse-free disease assessment date. The duration of CR, CR/CRh, CRh, CRp or CRi is defined similarly as duration of CRc.

    Time frame: Up to 24 months

  4. Duration of Overall Survival (OS)

    OS is defined as the time from the date of enrollment until the date of death from any cause. For a participant who is not known to have died by the end of study follow-up, OS is censored at the date of last contact.

    Time frame: Up to 24 months

  5. Duration of Event free survival (EFS)

    EFS is defined as the number of days from the date of enrollment to the date of earliest evidence of relapse, treatment failure, or death.

    Time frame: Up to 24 months

  6. Pharmacokinetics (PK) of ASP2215 in plasma: area under the plasma concentration-time curve during a dosage interval (AUCtau)

    AUCtau will be recorded from the PK plasma samples collected.

    Time frame: Up to 6 months

  7. PK of ASP2215 in plasma: maximum observed concentration (Cmax)

    Cmax will be recorded from PK plasma samples collected.

    Time frame: Up to 6 months

  8. PK of ASP2215 in plasma: pre-dose trough concentration (Ctrough)

    Ctrough will be recorded from PK plasma samples collected.

    Time frame: Up to 6 months

  9. PK of ASP2215 in plasma: area under the curve from time 0 to the time of the last measurable concentration (AUClast)

    AUClast will be recorded from PK plasma samples collected.

    Time frame: Up to 6 months

  10. PK of ASP2215 in plasma: time to Cmax (tmax)

    tmax will be recorded from PK plasma samples collected.

    Time frame: Up to 6 months

  11. Number of participants with negative minimal residual disease (MRD) status

    MRD testing will be performed on left over bone marrow samples taken at different time points during the study, and at end of treatment.

    Time frame: Up to 48 months

  12. Transplantation rate

    Transplantation rate is defined as the percentage of participants undergoing hematopoietic stem cell transplantation (HSCT) during the study treatment period.

    Time frame: 24 months

07

Study locations

18 sites
08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jul 2028, 66 months after the start.

Of 92 industry-sponsored phase 1/2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 73 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 91. This study's planned 66 months is close to that.

Counting every sponsor, half of 226 studies reached it within 73 months; a quarter within 48 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2022
First posted
Aug 30, 2022
StartActual
Jan 31, 2023
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Sep 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05520567
Responsible party
Sponsor
First posted
Aug 30, 2022
Start date
Jan 31, 2023
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Sep 11, 2026

Study contacts

Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gilteritinib · Venetoclax · Azacitidine

Start the discussion